Phio Pharmaceuticals Corp. (PHIO) Key Metrics
PHIO valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $10.1M
- Enterprise value
- −$1.1M
- P/E (TTM)
- —
- Forward P/E
- 0.3
- PEG ratio
- —
- Price / sales
- 48.0
- Price / book
- 0.9
- EV / EBITDA
- 0.6
- Dividend yield
- —
- Beta
- 0.84
PHIO key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPHIO returns How much profit the business earns on the capital it uses.
PHIO financial health Debt, liquidity and how easily interest is covered.
PHIO efficiency & capital use Working capital cycle and where the cash goes.
PHIO valuation history
PHIO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PHIO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PHIO cash returned to shareholders
PHIO price vs earnings per share
PHIO key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $6.3M | — | — | — | — | — | — | — | — | — |
| Enterprise value | −$14.7M | — | — | — | — | — | — | — | — | — |
| Price / book | 0.3 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −138.4% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −127.2% | — | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $1.05 | $1.80 | $6.84 | $40.18 | $108.00 | $290.52 | $1,015.74 | $1,960.20 | $33,026.40 | $42,471.00 |
| Per share | ||||||||||
| Revenue per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$1.45 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$1.33 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$1.34 | — | — | — | — | — | — | — | — | — |
| Cash per share | $3.51 | — | — | — | — | — | — | — | — | — |
| Book value per share | $3.37 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | $3.37 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 6.0M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −69.9% | −114.8% | −116.6% | −69.0% | −75.6% | −93.7% | −91.5% | −95.5% | −196.3% | −91.1% |
| Return on assets (ROA) | −63.9% | −94.7% | −97.6% | −59.5% | −64.6% | −74.0% | −75.7% | −75.8% | −142.3% | −73.3% |
| Return on tangible assets | −40.5% | −124.6% | −115.6% | −88.2% | −52.5% | −55.9% | −110.0% | −48.0% | −303.9% | −67.1% |
| Financial health | ||||||||||
| Total debt | — | — | $35,000 | $170,000 | $295,000 | $642,000 | $518,000 | — | — | — |
| Cash & short-term investments | $21.0M | $5.4M | $8.5M | $11.8M | $24.1M | $14.2M | $6.9M | $14.9M | $3.6M | $12.9M |
| Net debt | −$21.0M | −$5.4M | −$8.5M | −$11.6M | −$23.8M | −$13.6M | −$6.4M | −$14.9M | −$3.6M | −$12.9M |
| Debt / equity | — | — | 0.00 | 0.02 | 0.01 | 0.05 | 0.09 | — | — | — |
| Debt / assets | — | — | 0.00 | 0.01 | 0.01 | 0.04 | 0.06 | — | — | — |
| Current ratio | 49.37 | 5.65 | 5.71 | 6.42 | 8.06 | 6.91 | 3.88 | 8.69 | 1.69 | 5.16 |
| Quick ratio | 49.37 | 5.65 | 5.71 | 6.42 | 8.06 | 6.91 | 3.88 | 8.69 | 1.69 | 5.16 |
| Interest coverage | — | -32.0 | — | -65.5 | — | — | — | — | — | — |
| Working capital | $21.0M | $4.7M | $7.7M | $10.5M | $21.7M | $13.0M | $5.4M | $13.4M | $1.6M | $10.6M |
| Invested capital | −$884,000 | −$659,000 | −$725,000 | −$771,000 | −$1.8M | −$585,000 | −$668,000 | −$1.3M | −$1.7M | −$2.1M |
| Tangible asset value | $20.1M | $4.7M | $7.7M | $10.8M | $21.9M | $13.0M | $5.7M | $13.6M | $1.8M | $10.9M |
| Net current asset value | $20.1M | $4.7M | $7.7M | $10.5M | $21.5M | $12.4M | $5.0M | $13.4M | $1.6M | $10.6M |
| Graham net-net per share | $3.29 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | $4.1M | $1,000 | — | — | — |
| Share buybacks (net) | $0 | $1,000 | $11,000 | $28 | $1 | $15,000 | $0 | $0 | $0 | $0 |
| Capex / revenue | — | — | — | — | — | 435.6% | 342.9% | 3.6% | 1,353.3% | 21.1% |
| Capex / depreciation | 4.00 | 0.03 | 0.03 | 0.63 | 0.68 | 0.26 | 1.07 | 0.06 | 2.90 | 0.08 |
| Stock-based compensation / revenue | — | — | — | — | — | 3,117.8% | 1,428.6% | 204.3% | 2,093.3% | 3,978.9% |
| R&D / revenue | — | — | — | — | — | 85,190.3% | 20,476.2% | 3,134.8% | 35,800.0% | 28,500.0% |
| SG&A / revenue | — | — | — | — | — | 116,391.6% | 22,419.0% | 2,301.4% | 26,740.0% | 19,047.4% |
| Efficiency | ||||||||||
| Days payables outstanding | 27.2 | 45.6 | 41.4 | 1,004.2 | 961.0 | 75.5 | 57.7 | 44.8 | 48.5 | 70.1 |
| Payables turnover | 13.42 | 8.01 | 8.82 | 0.36 | 0.38 | 4.84 | 6.33 | 8.15 | 7.52 | 5.21 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Average payables | $344,000 | $455,000 | $718,000 | $531,000 | $505,500 | $768,500 | $679,500 | $530,500 | $714,000 | $1.0M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from PHIO's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PHIO valuation and financial ratios
Phio Pharmaceuticals earned a return on equity of −69.9% in fiscal 2025.
See the PHIO income statement, the PHIO chart for price history, or the PHIO stock overview for the latest quote and news.
PHIO key metrics FAQ
What is Phio Pharmaceuticals's return on equity?
Phio Pharmaceuticals's return on equity (ROE) was −69.9% in fiscal 2025: net income of -$8.7 million on average shareholders' equity of $12.4 million.
What is Phio Pharmaceuticals's free cash flow yield?
Phio Pharmaceuticals generated -$8.0 million of free cash flow in fiscal 2025, a free cash flow yield of −127.2% on its market value at year-end ($6.3 million).
What is Phio Pharmaceuticals's current ratio?
Phio Pharmaceuticals's current ratio was 49.37 at the end of fiscal 2025: current assets were 49.37 times current liabilities.